PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.

ABSTRACT:

Background

PrEP-001 Nasal Powder, a proprietary formulation of polyriboinosinic and polyribocytidylic acid effectively elicits a cellular innate immune response in nasal epithelium. The aim of these 2 studies was to investigate the safety and efficacy of PrEP-001 prophylaxis against rhinovirus (HRV-A16) and influenza-A (H3N2-IAV).

Methods

Healthy subjects randomly received 2 doses of PrEP-001 or placebo, 48 and 24 h pre-challenge with 10 TCID₅₀ of HRV-A16 (Study 1) or H3N2-IAV (Study 2).

Results

In Study 1, PrEP-001 reduced median total symptom score from 38.5 to 4.5 (p = 0.004), median symptom duration from 6.0 to 1.7 days and median mucus production from 15 g to 3 g. The percentage of subjects classified as ill was reduced 3-fold (placebo 73%, PrEP-001 23

SUBMITTER: Malcolm BA 

PROVIDER: S-EPMC7126195 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature